TMED7 Antibody

TMED7 Antibody Characteristics

TMED7 antibodies are polyclonal reagents developed for detecting human TMED7 in research applications such as Western blot (WB), immunohistochemistry (IHC), and immunoprecipitation (IP). Key commercial antibodies include:

Applications and Validation

• Western Blot:
  TMED7 antibodies detect bands at ~25 kDa (full-length isoform) and ~21 kDa (shorter isoform) in human cell lines (e.g., 293T, A431) . For example, ab126094 shows reactivity in 293T and A431 lysates at 1:1000 dilution .

• Immunohistochemistry:
  Strong cytoplasmic staining is observed in hepatocytes (liver) and moderate granular positivity in kidney tubules .

• Functional Studies:
  TMED7 antibodies have been used to study its role in TLR4 regulation, including co-localization with TRAM (TLR4 adaptor) and TAG (TRAM inhibitor) in late endosomes .

Immune Regulation

• TMED7 inhibits the MyD88-independent TLR4 pathway by disrupting the TRIF/TRAM complex, limiting interferon regulatory factor 3 (IRF3) activation .

• It facilitates TLR4 degradation in Rab7-positive late endosomes, terminating signaling post-lipopolysaccharide (LPS) stimulation .

• TMED7 interacts with TAG, a fusion protein derived from a read-through transcript of TMED7-TICAM2, enhancing TLR4 suppression .

Protein Trafficking

• TMED7 mediates anterograde transport of TLRs (e.g., TLR2, TLR4) from the endoplasmic reticulum (ER) to the Golgi via COPII vesicles .

• Truncated TMED7 lacking the coiled-coil domain disrupts TLR2/4 ER export, causing ER accumulation .

Expression and Clinical Relevance

• Tissue Distribution:
  TMED7 is ubiquitously expressed, with highest levels in the liver and lowest in skeletal muscle .

• Disease Associations:
  Upregulated in metastatic nasopharyngeal carcinoma, suggesting potential immunosuppressive roles .